Governance
CIRS is governed by its own dedicated advisory boards made up of external international experts from academia, industry, regulatory agencies and HTA bodies.
The Scientific Advisory Council (SAC) and HTA Steering Committee advise CIRS on workshops, special projects, publications as well as the research programme, to ensure neutrality and that the areas are unbiased and the programme meets the needs to all stakeholders.
The selection of Committee Members and Chairs is set out in the Terms of Reference of each committee.
CIRS Scientific Advisory Council (SAC)
Chair: Prof John Skerritt, Enterprise Professor of Health Research Impact, University of Melbourne, Australia
Vice Chair: Prof Hans-Georg Eichler, Consulting Physician of the Association of Austrian Social Insurance Institutions
From left to right: Prof Hans-Georg Eichler, CIRS SAC Vice Chair; Anna Somuyiwa, Head of CIRS; Prof John Skerritt, Chair of CIRS SAC; Dr Brian O'Rourke, Chair of CIRS HTA SC; Dr Tina Wang, Associate Director of CIRS' HTA Programme; and Dr Nick Crabb, Vice-Chair of CIRS HTA SC.
Agencies:
Prof Tony Lawler, Deputy Secretary, Health Products Regulation Group, Australian Government Department of Health and Aged Care
Dr Theresa Mullin, Director, Office of Strategic Programs, US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER)
Kelly Robinson, Director General, Pharmaceutical Drugs Directorate, Health Canada
Prof Bruno Sepodes, Chair, European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
Dr Xie Songmei, Deputy Director of Clinical Department Center for Drug Evaluation, National Medical Products Administration (NMPA), China
Dr Steffen Thirstrup, Chief Medical Officer, EMA
Dr Eveline Trachsel, Head of Authorisation and Vigilance, Swissmedic
Naoyuki Yasuda, Associate Executive Director for International Programs (PMDA), Japan
Industry:
Dr Fabio Bisordi, Global Head International Regulatory Policy, Roche
Donna Boyce, Senior Vice President, Global Regulatory Sciences, Pfizer
Jeffrey Francer, Vice President, Head of Global Regulatory Policy and Strategy, Global Regulatory Affairs, Eli Lilly and Co
Dr Amy McKee, Senior Vice President, Oncology Regulatory Science, Strategy & Excellence, AstraZeneca
Eddie Reilly, Chief Regulatory Officer, Sanofi
Dr Katrin Rupalla, Global Head Regulatory Affairs, J&J Innovative Medicines
Jerry Stewart, Head of Global Regulatory Policy, GlaxoSmithKline
Natalie Tolli, Vice President, Regulatory Affairs (Regulatory International, Regulatory Policy & Intelligence), Abbvie
Dr Max Wegner, Senior Vice President, Head of Regulatory Affairs, Bayer
Academic/Other:
Prof John Lim, Executive Director of Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School and Chairman, Consortium for Clinical Research & Innovation, Singapore
Dr Brian O’Rourke, Chair of CIRS HTA Steering Committee
Dr Charlie Preston, Senior Programme Officer, Regulatory Affairs, Bill and Melinda Gates Foundation
Prof Stuart Walker, Founder and Special Advisor, CIRS
CIRS HTA Steering Committee
Chair: Dr Brian O’Rourke, Former CEO and President, Canadian Agency for Drugs and Technologies in Health (now known as Canada’s Drug Agency)
Vice-Chair: Dr Nick Crabb, Chief Scientific Officer, National Institute for Health and Care Excellence (NICE)
HTA/Coverage bodies and regulatory agencies:
Dr Michael Coory, Medical Advisor, Technology Access and Assessment Division, Commonwealth Department of Health, Australia
Prof Hans-Georg Eichler, Consulting Physician, Association of Austrian Social Security Bodies, Austria
Prof Wim Goettsch, Professor of HTA, Utrecht University; Special advisor HTA, Zorginstituut Nederlannd (ZIN)
Niklas Hedberg, Chief Pharmacist, The Dental and Pharmaceutical Benefits Agency (TLV)
Suzanne McGurn, CEO and President, Canada’s Drug Agency
Dr Anja Schiel, Special Adviser, Lead Methodologist in Regulatory and Pharmacoeconomic Statistics, Norwegian Medicines Agency (NoMA)
Industry:
Dr Indranil Bagchi, Global Head, Pricing & Market Access, GSK
Lucia D’Apote, Executive Director, Global Regulatory Policy, Amgen
Melinda Hanisch, Director, Evidence Policy, Science and Regulatory Policy, Merck
Dr Adam Heathfield, Senior Director, Patient and Health Impact Innovation Centre, Pfizer
Shane Kavanagh, Vice President, Health Economics, Johnson & Johnson
Dr Antonia Morga, Head, New Product Planning, Global Value Evidence, Medical Affairs, Astellas Pharma Europe Ltd
Dr Vanessa Elisabeth Schaub, Access Strategy Chapter Lead, Global Access, Roche
Academic/Other:
Prof Finn Børlum Kristensen, Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director, Faculty of Health Sciences, University of Southern Denmark
Andrew Mitchell, Honorary Professor, The Australian National University
Dr Dan Ollendorf, Chief Scientific Officer and Director of HTA Methods and Engagement, Institute for Clinical and Economic Review (ICER), USA
Dr Detlev Parow, ex Head, Department of Medicines, Medical Remedies and Selective Contracts, DAK – Gesundheit, Germany
Dr Lotte Steuten, Deputy Chief Executive Officer, Office of Health Economics (OHE), UK
Dr Sean Tunis, Principal, Rubix Health